The Cumulative Risk to Human Health of Pharmaceuticals in New Jersey Surface Water

Human and Ecological Risk Assessment

Volumn 21, Issue 1, 2015, Pages 280-295

  Roden, Nicholas M ^a   Sargent, Edward V ^b,c   DiFerdinando, George T ^b   Hong, Jun Yan ^b   Robson, Mark G ^d  

^a PURDUE PHARMA L P   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c EV Sargent LLC   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

cumulative effect; drug interactions; human health; pharmaceuticals; risk assessment; surface water

Indexed keywords

EID: 85027945008     PISSN: 10807039     EISSN: 15497860     Source Type: Journal    
DOI: 10.1080/10807039.2014.913439     Document Type: Article

References (44)

1. Alvarez DA, Stackelberg PE, Petty JD, 2005. Comparison of a novel passive sampler to standard water-column sampling for organic contaminants associated with wastewater effluents entering a New Jersey stream. Chemosphere 61:610–22
2. American Water. 2011. Annual Water Quality Report—New Jersey. Available at http://www.amwater.com/njaw/About-Us/Corporate-Information/ (accessed August 2012)
3. AWWARF (American Water Works Association Research Foundation). 2008. Toxicological Relevance of EDCs and Pharmaceuticals in Drinking Water. Denver, CO, USA
4. Bercu JP, Parke NJ, Fiori JM, 2008. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regul Toxicol Pharmacol 50:420–7
5. Blanset DL, Zhang J, and Robson MG. 2007. Probabilistic estimates of lifetime daily doses from consumption of drinking water containing trace levels of N,N-diethyl-meta-toluamide (DEET), triclosan, or acetaminophen and the associated risk to human health. Hum Ecol Risk Assess 13:615–31
6. Bogen KT, Cullen AC, Frey HC, 2009. Probabilistic exposure analysis for chemical risk characterization. Toxicol Sci 109:4–17
7. Borgert CJ, Sargent EV, Casella G, 2012. The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol 62:313–28
8. Brooks BW, Huggett DB, and Boxall ABA. 2009. Pharmaceuticals and personal care products: Research needs for the next decade. Environ Toxicol Chem 28:2469–72
9. Bull RJ, Crook J, Whittaker M, 2011. Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater. Regul Toxicol Pharmacol 60:1–19
10. Cunningham VL, Perino C, D’Aco VJ, 2010. Human health risk assessment of carbamazepine in surface waters of North America and Europe. Regul Toxicol Pharmacol 56:343–51
11. Daughton CG and Jones-Lepp TL. (eds) 2001. Pharmaceuticals and Personal Care Products in the Environmental: Scientific and Regulatory Issues. American Chemical Society, Washington, DC, USA
12. Daughton CG and Ruhoy IS. 2009. Environmental footprint of pharmaceuticals: The significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 28:2495–521
13. de Jongh CM, Kooij PJF, de Voogt P, 2012. Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water. Sci Total Environ 427–428:70–7
14. Dolan DG, Naumann BD, Sargent EV, 2005. Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regul Toxicol Pharmacol 43:1–9
15. DIC (Drug Interactions Checker). 2011. Available at http://www.drugs.com/drug_interactions.html (accessed May 2011)
16. Ferrari B, Paxéus N, Giudice RL, 2003. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf 55:359–70
17. Fischer JM. 2011. Unpublished Data from 2001 Synoptic Survey of 30 Streams in New Jersey. Written Communications USGS (United States Geological Survey) Trenton, NJ, USA
18. Focazio MJ, Kolpin DW, Barnes KK, 2008. A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States—II Untreated drinking water sources. Sci Total Environ 402:201–16
19. ECOS (Environmental Council of the States). 2010. State Experiences with Emerging Contaminants: Recommendations for Federal Action, Washington, DC, USA
20. Kolpin DW, Furlong ET, Meyer MT, 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance. Environ Sci Technol 36:1202–11
21. Kumar A and Xagoraraki I. 2010. Human health risk assessment of pharmaceuticals in water: An uncertainty analysis for meprobamate, carbamazepine, and phenytoin. Regul Toxicol Pharmacol 57:146–56
22. Mao J, Mohutsky MA, Harrelson JP, 2011. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602
23. Mao J, Mohutsky MA, Harrelson JP, 2012. Predictions of cytochrome p450-mediated drug-drug interactions using cryopreserved human hepatocytes: Comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 40:706–16
24. Naumann BD and Sargent EV. 1997. Setting occupational exposure limits for pharmaceuticals. Occup Med 12:67–80
25. Pomati F, Orlandi C, Clerici M, 2008. Effects and Interactions in an Environmentally Relevant Mixture of Pharmaceuticals. Toxicol Sci 102:129–37
26. Post GB, Louis JB, Cooper KR, 2009. Occurrence and potential significance of perfluorooctanoic acid (pfoa) detected in New Jersey public drinking water systems. Environ Sci Technol 43:4547–54
27. Richardson SD. 2009. Water Analysis: Emerging contaminants and current issues. Anal Chem 81:4645–77
28. Roden NM, Sargent EV, Hong JY, 2013. The Cumulative Risk of Pharmaceuticals in New Jersey Surface Water to Human Health. Doctoral Dissertation. University of Medicine and Dentistry of New Jersey, PiscatawayNJ, USA
29. Sargent EV, Faria E, Pfister T, 2013. Guidance on the establishment of acceptable daily exposure limits (ADE) to support risk-based manufacture of pharmaceutical products. Regul Toxicol Pharmacol 65:242–50
30. Schwab BW, Hayes EP, Fiori JM, 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296–312
31. Teuschler LK 2007. Deciding which chemical mixtures risk assessment methods work best for what mixtures. Toxicol Appl Pharmacol 223:139–47
32. USEPA (US Environmental Protection Agency). 1997. Exposure Factors Handbook. EPA/600/P-95/002F. Office of Research and Development, Washington, DC, USA
33. USEPA. 2000a. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health. EPA/822/B-00/004. Office of Water, Washington, DC, USA
34. USEPA. 2000b. Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. EPA/630/R-00/002. Office of Research and Development, Washington, DC, USA
35. USEPA. 2003. Framework for Cumulative Risk Assessment. EPA/630/P-02/001F. Risk Assessment Forum, Washington, DC, USA
36. USEPA. 2007. Concepts, Methods, and Data Sources for Cumulative Health Risk Assessment of Multiple Chemicals, Exposures and Effects: A Resource Document. EPA/600/R-06/013F. Office of Research and Development, Washington, DC, USA
37. USEPA. 2011. Exposure Factors Handbook. EPA/600/R-090/052F. Office of Research and Development, Washington, DC, USA
38. USFDA (US Food and Drug Administration) 2012. Draft: Guidance for Industry: Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Center for Drug Evaluation and Research, Washington, DC, USA
39. USGAO (US Government Accountability Office). 2011. Environmental Health: Action Needed to Sustain Agencies’ Collaboration on Pharmaceuticals in Drinking Water. GAO-11-346. Washington, DC, USA
40. Waiser MJ, Tumber V, and Holm J. 2011. Effluent-dominated streams. Part 1: Presence and effects of excess nitrogen and phosphorus in Wascana Creek, Saskatchewan, Canada. Environ Toxicol Chem 30:496–507
41. Webb SF. 2001. A data based perspective on the environmental risk assessment of human pharmaceuticals iii—Indirect human exposure. In: Kummerer K (ed), Pharmaceuticals in the Environment: Sources, Fate, Effects and Risks. Springer, Berlin, Germany
42. Webb S, Ternes T, Gibert M, 2003. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142:157–67
43. WHO (World Health Organization). 2011. Pharmaceuticals in Drinking-water. WHO/HSE/WSH/11.05. Geneva, Switzerland
44. Williams RT (ed). 2005. Human Pharmaceuticals—Assessing the impact on aquatic ecosystems. Society of Environmental Toxicology and Chemistry (SETAC). Pensacola, FL, USA